2023-06-23 07:00:00
Successful Phase III for Bavarian Nordic
Bavarian Nordic reported data from a phase III clinical trial of its chikungunya virus vaccine candidate in adults over the age of 65. The serum met its primary endpoints, with a strong induction of neutralizing antibodies in 87% of the 413 trial participants. A second pivotal study in patients aged twelve to 64 is expected in the third quarter of 2023.
Lilly does not exceed Pfizer once morest migraine
In a phase IV trial comparing their efficacy in the treatment of migraine, theEmgality (galcanezumab) of Lilly was not superior to Pfizer’s Nurtec ODT (rimegepant). The primary endpoint of the study was the percentage of participants achieving a 50% or greater reduction in the number of monthly migraine days. Lilly said the response rates were similar, though.
I will tell you
source
EMA agrees to review Takeda’s fruquintinib
The European agency validated the MA application for fruquintinib for the treatment of adult patients with previously treated metastatic colorectal cancer. If authorized, this oral tyrosine kinase inhibitor targeting VEGFR1/2/3 would become the first of its type authorized in Europe. This compound is the subject of a license agreement between Takeda and Hong Kong biotech Hutchmed.
Selected for you
1687555299
#Dans #les #pipelines #Bavarian #Nordic #Lilly #Takeda
